PTPN11 and cancer: There is emerging evidence that Shp2 contributes to chemoresistance and cancer development [21, 22, 41], and therefore Shp2 allosteric inhibitors that interfere in both phosphatase and signal transduction have been developed as novel anti-cancer therapeutic agents [21].